Cowen and Company’s Moderna MRNA Stock Holding History

Cowen and Company’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-20,000	Closed	-$8.2K	–	666
2024 Q2	$8.2K	Buy	+20,000	New	+$2.53M	﹤0.01%	479
2023 Q1	–	Sell	-6,400	Closed	-$138	–	647
2022 Q4	$138	Buy	+6,400	New	+$1.05M	﹤0.01%	663
2022 Q3	–	Sell	-6,400	Closed	-$3K	–	725
2022 Q2	$3K	Hold	6,400	–	–	﹤0.01%	604
2022 Q1	$13K	Hold	6,400	–	–	﹤0.01%	477
2021 Q4	$97K	Hold	6,400	–	–	0.01%	372
2021 Q3	$418K	Buy	+6,400	New	+$2.36M	0.02%	206

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cowen and Company's MRNA Position: Q1 2023 in Review

Cowen and Company sold out of Moderna (MRNA) in Q1 2023, closing a stake of 16,324 shares — an estimated $2.93M sold.

Cowen and Company first reported a position in MRNA in Q3 2021 and held it in 6 quarters. The position peaked at $7.42M in Q3 2022. 1,017 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

Cowen and Company reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
Cowen and Company sold 16,324 Moderna shares in Q1 2023, an estimated $2.93M.
Cowen and Company first reported a position in Moderna in Q3 2021 and held it in 6 quarters.
Cowen and Company's Moderna position peaked at $7.42M in Q3 2022.
1,017 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.